The glycosylated N-terminal domain of MUC1 is involved in chemoresistance by modulating drug permeation across the plasma membrane

Kaori Miyazaki; Hisanao Kishimoto; Hanai Kobayashi; Ayaka Suzuki; Kei Higuchi; Yoshiyuki Shirasaka; Katsuhisa Inoue

doi:10.1124/molpharm.122.000597

Article Information

MOLPHARM-AR-2022-000597

DOI

https://doi.org/10.1124/molpharm.122.000597

Published By

American Society for Pharmacology and Experimental Therapeutics

Print ISSN

0026-895X

Online ISSN

1521-0111

History

Published online December 5, 2022.

© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.

Author Information

Kaori Miyazaki1,
Hisanao Kishimoto1,
Hanai Kobayashi1,
Ayaka Suzuki1,
Kei Higuchi1,
Yoshiyuki Shirasaka2, and
Katsuhisa Inoue1,*

¹Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Japan
²Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan

↵* Corresponding Author:
Katsuhisa Inoue, Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan. E-mail: kinoue{at}toyaku.ac.jp